Alex Dimitriu, MD

Menlo Park Psychiatry & Sleep Medicine

Neurogenesis Stimulating Compounds - Major Depression Disorder

A novel combination of two existing (and well tolerated) medications - buspirone (a potent 5HT1A agonist, often used as an ant-anxiety medication / or for depression augmentation) and melatonin has recently shown the unique promise of potentially enhancing depression outcomes, as well as stimulating neurogenesis. Of particular interest, is that patient did much better on this particular combination of medications than on either of the two compounds alone - suggesting a unique synergistic effect, which is currently without explanation. Response rates  in depression scores (CGI score <2) were much higher for the combination - 58%, versus buspirone alone - 38%, after six weeks of treatment. Very promising, and likely to soon be patented into a new drug. Read more about it: An exploratory study of combination buspirone and melatonin SR in Major Depressive Disorder (MDD): A possible role for neurogenesis in drug discovery

MENLO PARK  PSYCHIATRY & SLEEP MEDICINE  650-326-5888

CONDITIONS TREATED: anxiety, depression, attention deficit disorder, insomnia, bipolar disorder, and treatment resistant depression.

REGIONS COVERED:  We serve clients of the Bay Area, including the communities of Menlo Park, Palo Alto, Cupertino, Los Gatos, Los Altos, Mountain View, Portola Valley, Atherton, Sunnyvale, and San Jose